New FDA Approved Drugs-2024: Understanding Trends & Advances

1. New FDA Approved Drugs-2024: Understanding Trends & Advances New FDA Approved Drugs in 2024 and those awaiting approvals are going to create revolution in healthcare by focusing on treating life-altering medical conditions. The year 2024 begins with bright hopes for the ailing as some of the new medical wonders got the FDA approvals and many wait to get approved. These approvals ranging from pioneering cancer treatments to ground-breaking cures for incurable ailments represent beacons of hope in our persistent fight against illnesses. It's important to understand the fundamental trends and technological enhancements driving these breakthroughs as we sift through these inventions. https://www.lezdotechmed.com/

2. Toripalimab-tpzi is approved on October 27, 2023 to treat nasopharyngeal carcinoma, melanoma and urothelial carcinoma. Shanghai Junshi Biosciences has invented this ground-breaking drug to relieve the woes of the cancer patients. Eli Lily’s Zepbound (tirzepatide) got the FDA approval on November 8, 2023 to treat chronic obesity. This weight loss drug with GLP 1 receptors can reduce hunger and control the food intake. This tiny eye implant can reduce intraocular pressure (IOP) in patients. The FDA gave its approval nod on Dec 14, 2023 and it will be available for the consumers in the first quarter of 2024. Zelsuvmi is approved by the FDA on January 5, 2024 for treating contagious skin infection called molluscum contagiosum. It is a topical antiviral gel, with which patients can treat the infection at home itself. Lifileucel by Iovance Biotherapeutics is designed to treat advanced melanoma and is awaiting approval. If approved, it would be the first cell therapy to treat melanoma. Elevidys by Sarepta is the first gene therapy to treat DMD, which got the FDA approval in June 2023. https://www.lezdotechmed.com/

3. Pfizer’s Fordadistrogene movaparvovec is a single-injection gene therapy to address Duchenne muscular dystrophy (DMD). It is expected to be approved by the FDA in 2024. Resmetirom is a thyroid hormone receptor to treat liver fibrosis. It can regulate fat metabolism and inflammation in the liver. The FDA has given priority review and set a PDUFA date on March 14, 2024. Chugai Pharmaceutical Co., Ltd has submitted their innovative drug Crovalimab for FDA approval process. It is aimed to treat paroxysmal nocturnal hemoglobinuria (PNH), a life threatening blood disease. Merck’s Sotatercept awaits the FDA approval. It would be a breakthrough if this drug to treat pulmonary arterial hypertension (PAH) got the approval in 2024. Orchard Therapeutics’ Libmeldy is under FDA’s approval process. This stem cell therapy is invented to treat Metachromatic Leukodystrophy (MLD), a genetic disorder. People with chronic ailments are always at the mercy of the pharma companies for life saving drugs. When they fail to fulfill the promises they make, many innocent lives would be at peril. The drug manufacturers are responsible to market drugs or devices only after ensuring their safety. https://www.lezdotechmed.com/

4. However, the responsibility falls on the shoulders of all others too- from the physicians to the patients and their families to thoroughly learn about the drug or device they are going to use to make sure its efficacy and safety before use. If we fail in our responsibility, it may sometimes end up in facing adverse side effects and legal battles. LezDo TechMed handles medical record review and deposition summary services for attorneys handling personal injury claims. https://www.lezdotechmed.com/